![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by Lamdage22 on August 15, 2014, at 13:41:59
Glutamate receptor targeting drug. Pipeline.
http://www.drugdevelopment-technology.com/projects/elililleyantisycotic/
Posted by Lamdage22 on August 15, 2014, at 13:52:29
In reply to LY2140023.For Schizophrenia., posted by Lamdage22 on August 15, 2014, at 13:41:59
Posted by Lamdage22 on August 15, 2014, at 13:57:04
In reply to Re: LY2140023.For Schizophrenia., posted by Lamdage22 on August 15, 2014, at 13:52:29
Again, check out "see also"
Posted by jrbecker76 on August 19, 2014, at 11:16:01
In reply to Re: LY2140023.For Schizophrenia., posted by Lamdage22 on August 15, 2014, at 13:57:04
> Again, check out "see also"
Unfortunately, this drug (aka Pomaglumetad methionil) failed to find significant findings in Ph III trials and is more than likely abandoned. There actually was some interesting data from the trial that showed that a subgroup of patients with a particular genotypic biomarker for the 5-HT2a receptor did particularly well with it. But I'm not sure Lilly is still pursuing it. They might still be looking at this class for Bipolar d/o though.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.